Osteoking improves OP rat by enhancing HSP90‑β expression

Abstract

Osteoporosis (OP) is a chronic bone disease that affects individuals worldwide. Osteoporosis is primarily asymptomatic, and patients with OP suffer from pain, inconvenience, economic pressure and osteoporotic fracture (OPF). Osteoking, a Traditional chinese Medicine compound that originates from the Yi ethnic group, has been used for a number of years to treat fractures. In our previous study, osteoking exhibited therapeutic effects on rats with OPF by promoting calcium deposition. Based on bioinformatics and network pharmacology analyses of a component-target-disease database, heat shock protein HSP 90-β (HSP90-β), also known as HSP90-β, was identified to be a key target of osteoking in OP. High HSP90-β expression levels were observed in osteoporotic rats and rat bone mesenchymal stem cells (rBMScs) following osteoking treatment. After 12 weeks of administration in vivo, there was increased bone mineral density (BMd) (P<0.05), increased bone alkaline phosphatase (P<0.05), and improved bone microstructure in the osteoking group compared with those of the negative control group. In vitro, increased calcium deposition in rBMScs was observed after 4 weeks of osteoking treatment. These results suggest that the mechanisms of osteoking are closely associated with HSP90-β and activate the bone morphogenetic protein (BMP) signalling pathway, primarily through BMP-2. Osteoking treatment improves OP in rats by enhancing HSP90-β expression.

16S rDNA analysis of the intestinal microbes in osteoporotic rats

“…A DXA method was used to evaluate BMD in this study, and an OP model was successfully reproduced, as there was a statistically significant difference in BMD between the groups. This study reproduced OP rats at 23 weeks after OVX surgery [ 18 ], and intestinal contents were collected on days 0 and 70. In a previous study with estrogen deficiency induced by ovariectomy, Escherichia coli increased without the inhibition of estrogen [ 19 ], and it is known that intestinal microbes have an influence on maintenance of the balance of the bone microenvironment [ 20 ].…”

Network Pharmacology and Molecular Docking Elucidate the Pharmacological Mechanism of the OSTEOWONDER Capsule for Treating Osteoporosis

“…), Honghua ( Carthamus tinctorius L.), Sanqi ( Radix Notoginseng ), Duzhong ( Eucommiae Cortex ), Yangjinhua ( Daturae Flos ), Zuandifeng ( Schizophragma integrifolium ), and Biejia ( Trionycis carapace ). Previous studies have demonstrated that osteoking exerts anti-OP effects in OP rat models ( Sun et al, 2020a ; Sun et al, 2020b ). In addition, it has been found that osteoking anti-OP may be through reduction of reactive oxygen species ( Qin et al, 2019 ) or regulating rat bone marrow mesenchymal stem cell osteogenic and adipogenic differentiation ( Yu et al, 2019 ).…”

Osteoking ameliorates type 2 diabetes osteoporosis by promoting osteoblasts proliferation via PI3K/AKT/GSK-3β pathway activation

“…OK reduces osteocalcin levels, improves bone density and strength, and prevents osteoporosis in ovariectomized rabbits [13]. OK increase bone ALP levels in OP model rats by enhancing HSP90-β expression and protecting MC3T3-E1 cells from oxidative stress to improve OP [11,14]. Meanwhile, the potential of various natural medicines in reducing blood sugar in the prescription, including the active components of Carthamus tinctorius L, Panax ginseng C.A.Mey., Panax notoginseng (Burkill) F.H.Chen, Astragalus mongholicus Bunge and Citrus reticulata Blanco.…”